Apollomics Inc. Class A Ordinary Shares (APLM)vsAstraZeneca PLC (AZN)
APLM
Apollomics Inc. Class A Ordinary Shares
$14.00
0.00%
HEALTHCARE · Cap: $31.47M
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 683444% more annual revenue ($60.44B vs $8.84M). AZN leads profitability with a 17.2% profit margin vs -123.7%. AZN earns a higher WallStSmart Score of 64/100 (C+).
APLM
Hold36
out of 100
Grade: F
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for APLM.
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 431.9%
Revenue surging 380.8% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1305.0% — below average capital efficiency
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : APLM
The strongest argument for APLM centers on Operating Margin, Revenue Growth, Debt/Equity. Revenue growth of 380.8% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : APLM
The primary concerns for APLM are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
APLM profiles as a hypergrowth stock while AZN is a mature play — different risk/reward profiles.
APLM carries more volatility with a beta of 1.52 — expect wider price swings.
APLM is growing revenue faster at 380.8% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 36/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Apollomics Inc. Class A Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company is headquartered in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?